Chemotherapy-induced Neutropenia
44
5
5
27
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
11 trials with published results (25%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
6.8%
3 terminated out of 44 trials
90.0%
+3.5% vs benchmark
25%
11 trials in Phase 3/4
41%
11 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 27 completed trials
Clinical Trials (44)
Home Monitoring of Complete Blood Count Performed by Patients - a Pilot Study on the Implementation Process in South Baltic Countries.
G-CSF-Induced Bone Pain and Supportive Care Approaches
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor
Breath Analysis for the Detection of Invasive Fungal Infections
Clinical Study on the Safety, Efficacy and Pharmacokinetics of Telpegfilgrastim in Pediatric Cancer Patients with Chemotherapy
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Danish Elder Lymphoma Patient Hematopoietic Investigation
Study to Evaluate the Usability of PointCheck
Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma
Feasibility of Monitoring Health Data in Pediatric Patients Undergoing Chemotherapy
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Plinabulin iv Solution in Prevention of TAC Induced Neutropenia